SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)
$UTHR
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2025 | $414.00 | Underweight | Wells Fargo |
| 9/26/2025 | $569.00 | Outperform | RBC Capital Mkts |
| 6/2/2025 | $405.00 | Overweight | Cantor Fitzgerald |
| 4/25/2025 | Overweight → Equal Weight | Wells Fargo | |
| 4/21/2025 | $314.00 | Underperform → Neutral | BofA Securities |
| 7/11/2024 | $310.00 → $321.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/12/2024 | $213.00 → $215.00 | Sell → Neutral | Goldman |
| 2/5/2024 | $330.00 | Outperform | Leerink Partners |
8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
10-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint and several important secondary endpoints, including increasing odds of clinical improvement by 47%, in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) Ralinepag has the potential to redefine the PAH treatment landscape as the first and only once-daily oral prostacyclin, combining potent receptor affinity with continuous exposure to deliver long-term, durable efficacy and disease-mitigating outcomes United Therapeutics intends to submit a New Drug Application (NDA) for ralinepag to the U.S. Food and Drug Administration (FDA) by the second half of 2026 United Therapeutics will host a
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Looking ahead, our ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data that could unlock signific
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide a company overview and update on Monday, March 2, 2026, from 2:30 to 3:00 p.m. EST, at the TD Cowen 46th Annual Health Care Conference in Boston. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mission are one. We use our enthusiasm, creati
Wells Fargo initiated coverage of United Therapeutics with a rating of Underweight and set a new price target of $414.00
RBC Capital Mkts initiated coverage of United Therapeutics with a rating of Outperform and set a new price target of $569.00
Cantor Fitzgerald initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $405.00
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Kevin J. Tracey, M.D., to its Board on January 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122174254/en/Kevin Tracey was recently elected to United Therapeutics' Board of Directors. Dr. Tracey is President, CEO, and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research. He is a Professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Executive Vice Pres
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Looking ahead, our ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data that could unlock signific
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, February 25, 2026, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeuti
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 29, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision an
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)